<DOC>
	<DOCNO>NCT00725842</DOCNO>
	<brief_summary>The objective study determine relapse rate French patient population chronic hepatitis C ( CHC ) previously treat PegInterferon Alfa-2b ( Peg-IFN alfa-2b ) plus Ribavirin accord standard clinical practice . Treatment complete prior enrollment current study . The study also aim identify factor predictive relapse . Relapse rate define percentage patient negative viral load end treatment positive viral load 6 month end treatment .</brief_summary>
	<brief_title>Relapse Rate Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin Common Clinical Practice France ( P05484 ) ( Completed )</brief_title>
	<detailed_description>Non-probability sampling : The study population consist adult patient age 18 affected CHC previously treat first time Peg-IFN alfa-2b plus ribavirin achieve end-of-treatment response . Five hundred ninety patient must recruit order evaluate objective study . The patient must meet inclusion criterion meet exclusion criterion order include study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>The patient must demonstrate his/her continued willingness participate study . The patient must least 18 year age , either gender . Patients chronic hepatitis C ( genotype ) receive PegIFN alfa2b + Ribavirin first treatment hepatitis C. Negative HCVRNA end treatment ( 24 48 week accord product label appropriate ) , measure assay use institution . Only institution use assay limit detection 50 IU/mL less eligible . Patients complete treatment PegInterferon Alfa2b plus Ribavirin 4 week study entry . Patients positive HCVRNA end treatment ( 24 48 week accord product label appropriate ) . Patients treated period shorter enrollment period . Patients coinfected human immunodeficiency virus ( HIV ) . Patients coinfected hepatitis B virus ( HBV ) . Patients use appropriate effective method birth control end treatment ( accord legal recommendation ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>